Patient P-03225

Synthetic patientONX-7 · Day 138 · 45–54 · F · baseline S19Open companion preview

Therapy response

Stable

Tolerance

Deteriorating

GI state

Deteriorating

Inflammatory state

Stable

Nutritional resilience

Stable

Discontinuation risk

56%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S19
Day 102 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 102 GI-04 recommended — GI Support Protocol GI-04
Day 103 Patient accepted — Started GI-04 in the companion
Day 111 GI symptom burden −29% vs expected — GI Support Protocol GI-04
Day 117 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 102.

Primary contributors, last 14 days

Treatment adherence-12
Toxicity+9
GI instability+5
Inflammatory activity+3

What helped?

GI Support Protocol GI-04Day 102
Result: symptom burden −29%

LIFE OS recommendation

Dosing / Timing Recommendation DT-01

66%

probability of meaningful tolerance improvement

284 similar trajectories
80% showed improvement
median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 55 and rising
- WearableSleep 5.2 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 38/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 45
Autonomic recovery ↓45
- WearableResting HR 80 bpm
- WearableShort sleep window
Inflammatory signalling ↑25
- BloodInflammatory load index 54

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 2.6 · butyrate capacity 38/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 41 ms
Sleep: 5.5 h
Steps: 8,533
Resting HR: 79 bpm

Daily log: GI score 55, nutritional resilience 43, adherence 70.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03204	27%	S16	AD-05	improved	48
P-03105	25%	S12	AD-05	no change	60
P-03111	25%	S07	AD-05	no change	48
P-03351	25%	S07	AD-05	no change	51
P-03369	24%	S18	AD-05	no change	37
P-03424	24%	S12	AD-05	improved	41
P-03482	24%	S05	AD-05	no change	67
P-03034	23%	S14	AD-05	no change	30
P-03158	22%	S17	AD-05	no change	37
P-03380	22%	S16	AD-05	improved	34
P-03277	24%	S14	BR-03	improved	41
P-03031	44%	S16	CR-01	improved	49